Production Featured Articles

  1. 3 Innovations For Reducing Risk In Continuous Downstream Bioprocessing 4/21/2026

    Batch-to-continuous transitions in downstream bioprocessing carry real risks. Here's how advanced analytics, smarter buffer strategies, and single-use systems are changing that calculus.

  2. The Evolving Landscape Of HPAPI Contract Manufacturing 4/20/2026

    Surging demand for highly potent drugs is driven by targeted therapies, stricter containment standards, increased outsourcing, and the need for specialized, compliant manufacturing.

  3. The Future Of Sustainable Amorphous Dispersion Development 4/15/2026

    Sustainable amorphous dispersion cuts cost, risk, and timelines by removing solvent waste, simplifying manufacturing, strengthening supply chains, and scaling efficiently to commercialization.

  4. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

  5. FDA's New Flexible CMC Framework For CGT 4/14/2026

    The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.

  6. Is Your API Manufacturable — Or Just Technically Feasible? 4/13/2026

    Build manufacturability into your process from the start by evaluating scalability, cost, and cross-functional performance early to ensure consistent, efficient success at every stage of development.

  7. Video Series: The People Behind The Workcells 3/25/2026

    Learn more about the expertise and decision-making behind dependable workcell performance, offering a closer look at how consistent quality is built, step by step.

  8. The Evolution Of Parenteral Manufacturing For Sensitive Drugs 3/23/2026

    Parenteral manufacturing is advancing with better facilities, single‑use systems, continuous processing, and Annex 1 compliance to meet demand for specialised biologics and personalised therapies.

  9. Streamline HME Projects With Early Partner Engagement 3/18/2026

    Global partner delivering end‑to‑end drug development, manufacturing, and packaging with deep expertise, advanced facilities, and support across key modalities.

  10. FAQ: Fermentation And Biocatalysis In Modern Manufacturing 3/16/2026

    As companies race to adopt more efficient and environmentally responsible production methods, questions are emerging about how these biological systems work, where they deliver, and what challenges are involved.